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S u m m a r y  Superficial transitional cell carcinoma ofthe  bladder is a heterogeneous group
o f  tumours, and prediction of disease outcome in an individual patient is still 
impossible, In low-risk patients the initial treatment [transurethral resection 
(TUR)] should be followed by no or only one immediate intravesical instillation 
with a chemotherapeutic drug to prevent a recurrence due to tumour cell implan­
tation during TUR. Drug efficacy has been clearly demonstrated and adverse 
effects are very limited. Intermediate-risk patients should receive a course of 
additional intravesical instillations to reduce the recurrence rate with few adverse 
effects. All drugs seem to be equally effective, but the long term effects remain 
a question. In high-risk patients intravesical immunotherapy (BCG) should be 
given, Although toxicity is more pronounced, it is usually mild and adverse effects 
disappear after cessation of therapy. BCG (maintenance) therapy seenis to be able 
.to improve progression and ultimately tumour-related survival. It is important to 
know the advantages and disadvantages (adverse effects) of these treatment m o­
dalities to be able to individualise treatment as much as possible. The choice is
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difficult because several intravesical bladder cancer trials have not reached con­
sensus on this.
For patients with non-metastasised invasive bladder tumours chemotherapy 
can be given before (neoadjuvant) or immediately after (adjuvant) surgery or 
radiotherapy. Both strategies have some advantages and disadvantages. For both, 
however, efficacy still needs to be proven, and results of ongoing trials are needed. 
For metastasised or recurrent urothelial cell carcinoma MVAC (methotrexate, 
vinblastine, doxorubicin and cisplatin) chemotherapy remains the m ost effective 
treatment modality. Although initial response rates of between 40%  and 70% can 
be achieved, most patients have a recurrence of their cancer. Moreover, toxicity 
of these drugs also is considerable and limiting. Leucopenia is responsible for the 
majority of grade III and IV toxicides and subsequent dose modifications. In case 
of toxic deaths, a leucopenic sepsis is usually the cause. Most other adverse effects 
are acceptable or can be treated.
Bladder cancer is the second most common ma­
lignancy of the urinary tract, and accounts for 2% 
of all malignancies. In 1993 52 300 cases were 
registered in the US, while the number who died of 
bladder cancer that year was 9900. In 1992 in the 
Netherlands a total of 3777 bladder tumours was 
registered, which accounted for 5.7% of all malig­
nancies.111 Bladder cancer is predominantly seen 
in the sixth and seventh decade of life. The male 
to female ratio is approximately 4 : 1 .  These epi­
demiological data, however, are changing due to 
changes in the smoking behaviour among men and 
women.121
About two-thirds of bladder tumours will pres­
ent as superficial [pTa (papillary noninvasive car­
cinoma, limited to the bladder mucosa), pTl (tu­
mour not extending beyond the lamina propria of 
the bladder), carcinoma in situ (CIS; pre-invasive 
flat carcinoma)] transitional cell carcinomas 
(TCC)J3] The recurrence rate of these superficial 
tumours is high and depends on several factors. In 
our series of primary cases the 3-year risk of first 
recurrence ranged from 37% in low risk patients to 
77% in high risk patients (overall nearly 55%). In 
a review of 6 historical series with long term follow 
up, the recurrence rates after 5, 10 and 15 years 
were 65%, 81% and 88%, respectively.[4] Most re­
currences are found in the first years after transure­
thral resection (TUR)^ and have the same stage 
and grade. These tumours can be true reciirrences 
(regrowth after incomplete TUR or a result of im­
plantation of tumour cells during TUR) and/or new 
occurrences. Prevention of implantation of the tu­
mour is the rationale for immediate instillation of 
a chemotherapeutic drug.
The actuarial risk of disease progression in our 
series on bladder cancer patients was 10.2% after
3 years, with a 5-year relative survival rate of 
86%,*3] This is in concordance with data from the 
literature S(y^
With these data it is possible to select prognostic 
factors, like tumour grade and especially stage, re­
currence rate, multiplicity, size and localisation. 
With such factors, three risk groups can be con­
structed: low-risk patients, a minority, have a low 
chance of recurrence, and almost no progression. 
An example is a primary, small, solitary, well to 
moderately differentiated pTa tumour; intermedi­
ate-risk patients comprise the largest group, and 
consist of patients who develop a superficial recur­
rence without obvious progression; and a small 
group of patients have high-risk tumours with a 
high recurrence rate and a chance of progression 
despite maximal intravesical treatment. Patients 
with multiple recurrent pT 1 grade 3 tumours and/or 
CIS belong to this last group.
Many other prognostic factors, like DNA 
ploidy, chromosomal abnormalities and marker 
chromosomes, have been described in the past few 
decades, but none is able to predict recurrence or 
progression in an individual patient.^
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1. Initial Treatment
The cornerstone of the diagnosis of bladder can­
cer remains a TUR with or without mucosal biop­
sies. With this TUR specimen histology (> 90% 
TCC), tumour grade and stage can be determined. 
In case of a superficial bladder tumour a complete 
TUR with deep biopsies gives sufficient informa­
tion to evaluate the need for additional treatment. 
These intravesical instillations can be used to delay 
or prevent tumour recurrences (prophylaxis). In the 
case, however, of an incomplete resection (e.g. 
CIS), or contraindications against surgery, instilla­
tions are used to eradicate tumour (treatment).
Advantages of the intravesical route of admin­
istration are limited systemic uptake of the drug 
with an optimal contact between the tumour or tis­
sue at risk and the drug. Disadvantages are the local 
adverse effects in the bladder due to high local drug 
concentration and the need for transurethral manip­
ulation. Instillations can be done with chemothera­
peutic agents or immunotherapeutic agents. In low- 
risk patients the need for adjuvant treatment is 
low.t8] In the intermediate risk group intravesical 
instillations may be used to decrease the recurrence 
rate. In patients with high-risk tumours intravesical 
immunotherapy could be considered, although the 
higher efficacy comes at a cost of more adverse 
effects.
r
2. Additional Therapy of 
Superficial Bladder Cancer
2,1 Intravesical Chemotherapy
Because most chemotherapeutic drugs are cell 
cycle-specific, repeated instillations seem more ef­
fective than single instillations. Although weekly 
or monthly instillations might be very practical, 
they are probably not ideal from a molecular bio­
logical (cell cycle) point of view,
For chemotherapeutic drugs, a molecular 
weight of less than 200  and subsequent systemic 
absorption and toxicity are important. Local ad­
verse effects, like drug-induced cystitis, are the 
main adverse effects, increasing with the number 
and frequency of instillations and with the dose.
2.1.1 Thiotepa
Thiotepa is relatively inexpensive and is not cell 
cyclespecific. It has a low molecular weight of 189, 
and thus absorption and systemic toxicity can oc­
cur. Usually 30 to 60mg is used, although 30mg in 
30ml seems to be as effective as 60mg in 60 mlJ91 
After 6 weekly instillations treatment is generally 
continued for 1 year with monthly instillations.
Toxicity is mainly due to systemic absorption 
(leucopenia and thrombocytopenia in approxi­
mately 10%) and 25% of patients have irritative 
bladder complaints.[l0]
In 10 small series, thiotepa as definitive therapy 
for papillary bladder tumours has had a moderate 
success rate (complete responders) of approxi­
mately 38% (109 of 285).[II,l2l
In a large randomised trial (n = 379), no advan­
tage of thiotepa was reported using single immedi­
ate instillations after a complete TUR J 131 For other 
adjuvant treatment schedules Lamm*14! recently 
compared the recurrence rate of thiotepa (45%) to 
the recurrence rate in control groups (62%) in a 
series of 10 controlled studies with 1009 patients. 
The results depended on the follow-up period and 
in 5 of the 10 series failed to reach statistical sig­
nificance, including the 3 largest series. Two other 
large series also failed to show a statistically sig­
nificant advantage for thiotepa, in spite of a lower 
recurrence rate in the treated patients In 2 
other controlled studies thiotepa was proven to be 
equally effective compared with doxorubicin J17*1X1
In summary, thiotepa is inexpensive, but its ef­
ficacy is questionable. Adverse effects such as 
myelosuppression and chemical cystitis are not fre­
quent and usually mild.
2 .1.2 Doxorubicin
Doxorubicin has a relatively high molecular 
weight of 580, and thus its absorption and systemic 
toxicity are extremely rare. The dose of doxo­
rubicin ranges from 30 to 100mg in several instil­
lation schedules. Its main adverse effect is chemi­
cal cystitis in 25% of patients.*10,1^
The average complete response rates of doxoru­
bicin used as definitive treatment for papillary tu­
mours was 38% (273 of 712), depending on the
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dose used. L121 For CIS the reported success rate was 
63% (77 of 122), but the numbers were small.
In his review, Lamm^,4J found no significant ad- 
vantage of doxorubicin (recurrence rate of 38 ver­
sus 56% in control patients) in the prophylactic 
setting. The Japanese Urological Cancer Research 
Group found a significant advantage for doxo­
rubicin with regard to recurrences, but they found 
no advantage of a maintenance schedule over a 
course of intravesical instillations.[20,211
In summary, in the treatment of bladder cancer 
patients, doxorubicin is a relatively safe drug with 
reversible chemical cystitis occurring in approxi­
mately 25% of the patients. The success rate of 
doxorubicin is slightly less than 40%, with a doubt­
ful advantage over no additional treatment with the 
drug. Doxorubicin maintenance is clearly of no ad­
ditional value.
2.1.3 Mitomycin
Mitomycin has a molecular weight of 329 and 
thus is absorbed only to a small extent. The dose 
varies between 20 and 60mg per instillation. In a 
recent review, the adverse-effects of leucopenia 
and thrombocytopenia were both found in only 4 
of 613 (0 .7 %) patients.[ 101A more frequent adverse 
effect is chemical cystitis, which is seen in approx­
imately 15% of patients.10^ In our series, drug- 
induced cystitis and (culture proven) bacterial cys­
titis were seen in 20 to 25% of the patients.[22,23] 
Allergic reactions, mainly skin reactions such as 
palmar rash, are found in approximately 10%J10,241 
Most adverse effects disappear after cessation of 
therapy.
The overall success rates for definitive mitomy­
cin therapy in papillary lesions is 43% (270 of 627) 
and for CIS 58% (51 of 88).1121 For prophylactic 
use, the advantage of mitomycin (15% higher suc­
cess rate) over no treatment is not clear.114! The 
advantage of mitomycin maintenance therapy is 
controversial.
In summary, systemic adverse effects for mito­
mycin are rare. The frequency of drug-induced 
cystitis is comparable to other chemotherapeutic 
drugs. In approximately 10% of the patients, (re­
versible) allergic reactions are seen. The response
rates after mitomycin are around 50% and seem 
higher than of other chemotherapeutic agents. Our 
results with mitomycin have been better than the 
results in most other reports.
2.1.4 Etoglucid
Experience with etoglucid in superficial blad­
der cancer is limited. With a molecular weight of 
262, it is poorly absorbed and systemic adverse 
effects are rare. The EORTC-GU group (study 
30790) found exactly the same yearly recurrence 
rate (0.29) for intravesical therapy with doxorubi­
cin (n = 165) and etoglucid (n = 156).[25] This was 
significantly better than the yearly recurrence rate 
of 0.65 in the control group (n = 70).
2.1.5 Epirubicin
Experience with epirubicin is increasing. To 
date, its reported adverse events seem mild. Mild 
chemical cystitis has been observed in approxi­
mately 15% of patients, while systemic toxicity ap­
pears to be absent.1261 In an EORTC study with a 
single immediate instillation of 80mg of epirubi­
cin, chemical cystitis was only seen in 6 .8 % of pa- 
tientsJ27^  The efficacy of epirubicin was signifi­
cantly better than that of sterile water in patients 
with a single superficial tumour (p < 0 .0001 ).
In summary, toxicity of epirubicin seems lim­
ited to drug-induced cystitis and seems less fre­
quent than with other drugs (15% or less). Results 
about the efficacy of epirubicin are as yet too pre­
liminary.
Similarly, experience is very limited with other 
intravesical chemotherapeutics, such as cisplatin 
and mitoxantrone.
Several additional drugs have been used to im­
prove the efficacy of intravesical chemotherapy.
In a bladder cancer cell line, an effort was made 
to improve cell kill by adding dimethyl sulfoxide 
(DMSO).t281 However, the addition of 4% DMSO 
to 4  frequently used intravesical drugs failed to im­
prove cytotoxicity. Recently, it was even suggested 
that intravesical DMSO might promote bladder 
carcinogenesis in miceJ291
Verapamil is a calcium antagonist which can re­
verse multi-drug resistance (MDR). In vitro vera­
pamil increased the cytotoxicity of doxorubicin by
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a factor of 2.5 .1301 Preliminary clinical data on the should be considered. Maintenance therapy has 
intravesical use of verapamil, however, have more local and systemic toxicity.[40} 
shown it to confer neither an additional advantage,
nor to produce increased toxicityJ31!
Local adverse effects (cystitis-like complaints) 
are found in over 90% of the patients and increase 
with the number of instillations J4i| They are easily 
treated with nonsteroidal anti-inflammatory drugs. 
Haematuria, although seldom severe, is seen in 
43% of patients. Systemic adverse effects such as 
fever (28%), malaise (24%) and nausea (8%) gen­
erally subside spontaneously. Severe adverse ef­
fects (fever >39.5°C, genital infections, haemat­
uria, BCG pneumonia/hepatitis/sepsis) are seen in 
about 5% of all patients,[421 In these patients ther­
apy should be stopped, and eventually antituber- 
culous therapy should be started. Only few fatal 
Clinical experience to date with intravesical in- complications have been encountered, and trau- 
terferon in superficial bladder cancers is very lim- matic catheterisation seems to play an important
2.2 Intravesical Immunotherapy
In 1976, the era of intravesical immunotherapy 
stalled with the introduction of intravesical bacil­
lus Calmette-Guerin (BCG) .t321 Since then, several 
other immunotherapeutic drugs have been used 
(interferon, interleukins, keyhole-limpet haemo- 
cyanin, bropirimine), although in limited (by the 
number of patients) clinical studies.
2.2 .11nterferon
ited. The optimal dose remains a question, and clin­
ical results have been less than those observed with
B C G J 33^
2.2.2 Bacillus Calmette-Guerin (BCG)
The mechanism of action of BCG remains un­
clear. There is a combination of a clear inflamma­
tory effect (the nonimmunological response) and a 
nonspecific and specific immunological response 
(humoral and cellular).
The optimal dose seems to be 5 X 108 to 5 x  109 
colony-forming units (CFU), although similar suc­
cess rates, with less toxicity, have been reported 
with very low doses of BCGJ35"37! even in high- 
risk patients.138! Intravesical instillation of BCG is 
accepted as the best route of administration. Com-
role in these cases. Therefore, treatment should be 
postponed for one week in case of a traumatic 
catheterisation.
The clinical results of BCG have been good. 
With BCG the recurrence rate of more than 60% 
without additional therapy decreases to 35% or less 
with a minimal follow up of I yearj40* BCG is su­
perior to intravesical chemotherapy, but at the cost 
of inducing more adverse effects. A recent SWOG 
study, for example, showed a clear significant ad­
vantage of BCG over mitomycin J431 In two of our 
own studies, however, this advantage of BCG 
could not be confirmed.122,23! In fact, mitomycin 
toxicity was significantly less in our trials. Patient 
selection, prognostic profile and differences in
bination with intradermal administration does not treatment schedules and dose can partly explain
improve the results. [39J After a complete TUR of a these conflicting results.
superficial tumour, the initial schedule is a course After an incomplete endoscopic resection, BCG
of 6 weekly instillations. In high-risk patients (re- can be used as therapy, with success rates of 60 to
currences, CIS, etc.), a second course of 6 instilla- 70%. In case of CIS, the success rates of BCG vary
tions or maintenance therapy (e.g. monthly instil- between 42 and 83% (patients at least 1 year free
lations for 1 year) can be given. Both regimens will of recurrences as seen on cystoscopy and cytol-
improve the success rates. A second course seems ogy)J401
most useful in patients who respond well to the Although at this moment BCG seems to be the
initial course of BCG and ultimately have recurrent drug of choice for high risk superficial TCC, many
disease. However, in patients failing both courses, questions remain unanswered, especially about the
a significantly higher risk for muscle invasion by mechanisms of action, the optimal dose and clini-
the cancer is found, so more aggressive therapy cal schedule.
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2.2.3 Bropirimine
In high-risk patients failing intravesical BCG, 
more aggressive treatment such as cystectomy 
seems inevitable because of the high risk of tumour 
progression to muscle invasive disease. For such 
patients oral bropirimine might be an alternative.
Bropirimine is a biological response modifier 
which influences both humoral and cell-mediated 
immune responses. Its activity approached that of 
BCG in an animal model.[441
Adverse effects are mainly mild to moderate 
’flu-like symptoms (fever, nausea, fatigue and 
headache). Cardiac dysrhythmias have been re­
ported in patients with coexisting cardiac dis­
ease J45l
In superficial bladder cancer, a phase II study 
was performed with a dose of 3000 mg/day 
(amended from 4500 mg/day because of the car­
diac dysrhythmias).[46l In 47 evaluable patients, 26 
complete responses (negative cystoscopy, cytol­
ogy and biopsy) were seen (55%), also in some of 
the patients who were BCG failures.
3. Long Term Efficacy Results In 
Superficial Bladder Cancer
In a review of long term results of intravesical 
chemotherapy, the short term cancer recurrence 
rate decreased from 58 to 41% in a group of 2,799 
patients receiving cancer chemotherapy [thiotepa 
(n = 1009), mitomycin (n = 859), doxorubicin (n = 
722) and etoglucid (n = 209)] versus those receiv­
ing no treatment,1141 with comparable results for 
different drugs. This reduction in recurrence rate, 
however, disappeared within a period of 5 years. A 
meta-analysis of 4 European Organisation for Re­
search and Treatment of Cancer (EORTC) and 2 
Medical Research Council (MRC) trials, however, 
showed a long-term (median follow up 7.7 years) 
reduction of the recurrence rate after intravesical 
chemotherapy.1471 An advantage of intravesical 
chemotherapy in reducing tumour progression, a 
more important goal, could not be confirmed^14,47,48! 
although interpretation and comparison of many 
studies should be done with caution because of a 
number of variables in the studies. Comparing the
long term follow-up of 1938 treated patients with 
a group of 2607 untreated controls, drug treatment 
caused no significant progression or survival ad­
vantage. ^ 1
A combination of controlled studies (1423 pa­
tients) also failed to demonstrate an advantage: the 
progression rate was 6 .6 % for treated patients and 
7.2% for controls. Although it remains a question 
why obvious reduction of recurrence rates does not 
influence progression, an explanation might be 
that intravesical chemotherapy does not reach the 
deeper layers of the bladder, where the potentially 
invasive tumours might originate.
BCG, on the other hand, seems to be the only 
drug which also reduces tumour progression and 
even bladder cancer deathJ14,49! Lamm, for exam­
ple, observed an improved survival in patients 
treated with maintenance therapy in responders to 
an initial 6 -week course.[l4l
4. Invasive Bladder Cancer
An interesting approach is the use of primary 
(neoadjuvant) chemotherapy in patients with lo­
cally advanced (>pT2) bladder cancer. In spite of 
negative screening, many of these patients will 
have recurrent disease after treatment with curative 
intent (radical surgery or radiotherapy) dependent 
on the initial stage of the tumour. It is also known 
that combinations of chemotherapeutic agents 
based on cisplatin (C) and methotrexate (M), with 
vinblastine (V) or with vinblastine and doxoru­
bicin (A) can give response rates of 55 to 70%, with 
complete remissions of 25% or more for CM, CMV 
and MVAC.[50"52J Theoretically, therefore, neo­
adjuvant chemotherapy prior to local definitive 
therapy has potential advantages, as was shown in 
phase II studies.153!
The first results of randomised studies indicated 
that there might be some advantage of neoadjuvant 
chemotherapy. A Nordic study, for example, indi­
cated a 15% overall survival advantage after neo­
adjuvant chemotherapy and cystectomy with a 5- 
year follow-up.I54^ In a combined MRC/EORTC 
study, 975 patients with locally advanced bladder 
cancer were randomised for no or 3 cycles of CMV
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(cisplatin 100 mg/m2, methotrexate 30 mg/m2 and 
vinblastine 4 mg/m2; CMV) prior to definite surgi­
cal or radiation therapy. Preliminary results after a 
median follow up of 22 months showed no differ­
ence in survival between neoadjuvant CMV or no 
CMV [Hazard ratio (HR) 0.95, p = 0.63]J551 Over­
all disease-free 2 -year survival rates were 51 ver­
sus 45% (HR = 0.84, p = 0.06), but this might have 
been due to arm-dependent biases in the time to 
diagnosis of the progression. In patients treated 
with cystectomy, CMV appears to have clear activ­
ity on the primary tumour (33 versus 12% patho­
logical complete responses). This was also found 
by Logothetis et al.[56] They compared 5 post­
cystectomy courses of MVAC to a combination of
2 pre- and 3 postoperative courses. The second in­
terim analysis showed no survival difference, but 
in the ‘neoadjuvant' group 28 versus 2 % pathologi­
cal complete responders were seen (p = 0.004), im­
proving local resectability or offering the possibil­
ity of organ preservation. In general, low tumour 
stage (pT2) and downstaging to pTO are important 
prognostic factors for neoadjuvant chemotherapy.
Compared with neoadjuvant treatment, immedi­
ate adjuvant chemotherapy for proven locally ad­
vanced disease has the advantage that the patho­
logical stage is precisely known at the moment of 
the start of the chemotherapy. A disadvantage, 
however, is that there is no measurable disease. 
Moreover, bowel in the urinary tract can absorb 
chemotherapeutic agents if not drained. Skinner et 
al. reported a randomised trial comparing adjuvant 
CISCA (cisplatin, cyclophosphamide and doxo­
rubicin) treatment versus observation after radical 
cystectomy and lymph node dissection.1571 In all, 
91 patients with T3, T4 or N+M0 tumours were 
randomised. There was a significant advantage in 
the treated group for time to progression (p =
0 .0 0 1 ) and survival (p = 0.006), but the group was 
small and not uniform, Freiha et al. also found a 
progression advantage (freedom of progression 37 
versus 12 months, p = 0.01) using 4 additional cy­
cles of CMV in 50 patients with a median follow 
up of 62 months.1581 However, they did not find a 
significant survival advantage (median survival 63
versus 36 months, p = 0.32), possibly because some 
relapsing patients could also be salvaged by CMV 
chemotherapy
5. Treatment of Disseminated 
Bladder Cancer
We are regularly confronted with patients who 
already have metastasised bladder cancer or a re­
lapse after intended curative treatment. In these pa­
tients chemotherapy should be considered.
Since the first report in 1985, the MVAC regi­
men is now widely used in urinary tract cancers. I591 
The initial response rates were very promising [CR 
50%, and partial response (PR) 21%]. In a follow- 
up study CR and PR rates were both 36%.I601 More­
over, there was a significant survival advantage in 
the CR group: median survival of more than 38 
months compared to 11 months in the PR group, 
and 8 months for the non-responders. The most fa­
vourable sites of métastasés were lungs, followed 
by retroperitoneal lymph nodes and bone. In a 
randomised trial, Logothetis et aî. found somewhat 
lower response rates, but response rates (p < 0.05) 
and survival (p = 0.0003) were significantly better 
than with CISCAJ611 In another randomised trial 
MVAC was shown to be significantly superior to 
cisplatin monotherapy with regard to response rate 
and survival (p = 0.0002).I621 In spite of these 
promising initial CR rates, however, the majority 
of patients in these series relapsed.
Toxicity of MVAC remains a major limiting fac­
tor. Different grades of myelotoxicity are seen in 
almost all patients, and subsequent treatment- 
related deaths due to a nadir sepsis have been re­
ported. Other adverse effects are mucositis, nausea, 
vomiting, alopecia and renal toxicity. MVAC is sig­
nificantly more toxic than cisplatin monother­
apy.[62J Toxicity data of some studies, including our 
own experience, are listed in table I. MCV is less 
toxic than MVAC, and is therefore also widely 
used. Efficacy of MVAC and MCV have, however, 
never been compared in a randomised study. Car- 
boplatin is less toxic than cisplatin, but it also 
seems to be less effective^631
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Myelotoxicity during MVAC therapy can be 
prevented or diminished with haematopoietic 
growth factors, such as granulocyte-colony stimu­
lating factor (G-CSF) or granulocyte-macrophage 
colony-stimulating factor (GM-CSF). Moore et 
al.[64l found approximately 40% > grade 3 
granulocytopenia when the first 2 cycles of MVAC 
were combined with GM-CSF compared with 80% 
in their earlier experience. In addition, nadir plate­
let and granulocyte counts were significantly 
higher. An ongoing EORTC trial will give more 
insight in to the value of this regimen.
In patients relapsing after MVAC chemotherapy 
the possibilities are very limited. Based on some 
promising results of L o g o th e tis ,th e  EORTC has 
started a phase II trial to study the efficacy of a 
combination of fluorouracil, cisplatin and inter- * 
leron-a as second-line therapy in patients with pro­
gressive metastatic transitional cell carcinoma of 
the urinary tract despite previous chemotherapy.
Testing of new drugs as a single agent (like 
gemcitabine) or in cisplatin-based combinations 
(like paclitaxel, vincristine, etoposide or ifosfam- 
ide) is ongoing. Results, however, are too prelimi­
nary to draw any conclusions about their efficacy 
or toxicity.
6. Conclusions and Recommendations
The question of drug therapy in superficial, in­
vasive and metastasised bladder cancer remains 
difficult because results of clinical trials, to date, 
have not reached a consensus on all patients.
In patients with superficial bladder tumours at 
low risk for recurrence and progression, the initial 
transurethral resection should be followed by no or 
only one immediate intravesical instillation with a 
chemotherapeutic drug to prevent a recurrence due 
to tumour cell implantation during transurethral re­
section. Efficacy of this regimen has been clearly 
demonstrated and side effects have been very lim­
ited. Intermediate risk patients should receive a
Table I. Toxicity data of some MVAC studies
Reference
Sternberg et al.[60] Tannock et al.[66] Loerher et aL{62J Witjes et al.1671
No. of patients 
Leucopenia
Nausea, vomiting
Nephrotoxicity
Mucositis
Neurotoxicity
Toxic death
121
Gl: 7%
Gli: 27% 
Gill: 38% 
GIV: 20% 
Sepsis: 25%
Gl: 45%
G!l: 21% 
Gill: 7%
G I: 29%
Gil: 7%
Gill: 2%
Gl: 19%
Gil: 17% 
Gill: 12% 
GIV: 1%
Gl: 2%
Gil: 1%
3 (4%)
41
<0.5: 90% 
Sepsis: 41%
126
Glil or IV: 24% 
Sepsis: 6%
6 (15%) 
Admission
Gill or IV: 12%
>1.5: 34% 
>2.0: 17%
Gill or IV: 7%
Mild: 17% Gill or IV: 17%
Moderate to severe: 15%
Gill or IV: 5%
1 (sepsis) 5 (4%)
(4 due to sepsis)
28
Gl: 20%
Gil: 40-50% 
GUI: 20-30%
±100% usually mild
Gl-ll: 1 0 -20%
(2 patients stopped 
treatment3)
Mild in 23/28 (82%)
1 (3.6%)
1 (sepsis)'
a Kidney function at start already borderline.
b Second death during therapy from an intestinal bleeding with normal laboratory values and a complete response. 
Abbreviations and symbols: MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; Gl = Grade I; Gil = Grade 
GIV = Grade IV.
II; Gill = Grade
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course of additional intravesical instillations with 
mitomycin to lower the recurrence rate. We have 
found mitomycin to be effective with few and re­
versible adverse effects. However, although all 
chemotherpeutic drugs appear to be equally effec­
tive on a short term basis, their long term (5 years 
and more) effects with regard to recurrence and 
progression remains a question. In high risk pa­
tients intravesical immunotherapy with BCG is the 
standard preferred treatment. Although toxicity 
with BCG is more pronounced, it is usually mild 
and reversible with cessation of drug therapy. 
Maintenance BCG therapy seems to be able to de­
crease the tumour progression rate and therefore 
improve tumour-related survival.
The value of neoadjuvant systemic chemother­
apy in patients with non-metastasised invasive 
bladder tumours has not been proven. Adjuvant 
chemotherapy immediately after surgery or radio­
therapy remains in the experimental stage, and thus 
results of ongoing trials are needed. For metasta- 
sised or recurrent urothelial cell carcinoma, MVAC 
(methotrexate, vinblastine, doxorubicin and cis­
platin) remains the most effective treatment modal­
ity despite considerable and limiting systemic toxi­
city (predominantly leucopenia). Initial response 
rates between 40 and 70% can be achieved, al­
though most patients will ultimately suffer a recur­
rence of their cancer.
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